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Abstract
Background Gender differences in chronic liver disease (CLD) have been partially investigated. To extend the present 
knowledge, we evaluated 12,263 patients with CLD enrolled in two national surveys (9997 in 2001 and 2557 in 2014).
Methods The two surveys prospectively recruited patients aged ≥ 18 referring to Italian liver units throughout the country 
using a similar clinical approach and analytical methods.
Results The overall male to female ratio (M/F) was 1.4 (7138/5124). Compared with females, males were significantly more 
likely to be younger (52.9 vs. 58.7 yrs.), with HBV infection alone (13.2% vs. 9.2%) and with alcoholic liver disease alone 
(11.4% vs. 6.9%), but less likely to show HCV infection alone (48.0% vs. 67.9%). A male preponderance was observed in 
HBV-related cases (1.99) and in alcoholic-related cases (2.3), a preponderance observed both in the 2001 and in 2014 cases. 
In HCV-related cases, however, females predominated in 2001 (M/F 0.9) and males in 2014 (M/F 1.5).The rate of cirrhosis 
in alcohol-related etiology was close to 36% in both genders, a finding much higher than that observed for both sexes in HBV 
and HCV etiologies.Both males and females enrolled in 2014 were older (p < 0.001) and with a higher rate of cirrhosis and/
or HCC (p < 0.001) than those investigated in 2001. There was a remarkable increase over time in the proportion of male 
abstainers (36.7% in 2001 and 64.3% in 2014).
Conclusion This study highlights important inter- and intra-gender differences in the characteristics and etiological factors 
of patients with CLD in Italy.
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PBC  primary biliary cholangitis
US  ultrasound
Introduction
Because of a less frequent risk of exposure to Hepatitis 
B virus (HBV) and an easier clearance of this infection, 
females harbour chronic HBV infection less frequently 
than males [1]. Another relevant gender difference in HBV-
related chronic liver diseases (CLD) is the more rapid pro-
gression of the disease in males than in females [2–11], 
partially due to the low production in males of estradiol, a 
potent anti-oxidant able to suppress hepatic fibrosis in ani-
mal models and to inhibit the generation of reactive oxygen 
species in primary culture [12].
Also hepatitis C virus (HCV) infection has been reported 
to be more frequent in men than in women, with a 2:1 male 
to female (M/F) ratio both in USA and Europe [13, 14], with 
nearly two-thirds of the subjects infected having liver abnor-
malities [15, 16]. Gender plays an important role in disease 
progression: male sex has been identified as an independent 
predictor of a more severe form [17]. Liver fibrosis increases 
with increasing age both in males and in females, show-
ing a linear course in men and a biphasic course in women 
[17]. Previous studies have identified a protective effect of 
estrogens on fibrogenesis due to an inhibition of stellate cell 
proliferation [18–20]. Accordingly, long-term studies on the 
natural course of HCV infection in anti-D immunoglobulin-
contaminated female cohorts showed low rates of disease 
progression. Only 2% in an Irish study and 0.5% in a Ger-
man cohort had developed liver cirrhosis after a follow-up of 
17 and 25 years, respectively [21, 22]. Thirty-five years after 
infection, however, 9% of the women in the German cohort 
had developed liver cirrhosis, suggesting that in women the 
disease progression may change over time in relation to the 
reproductive status. This has been proven in a subsequent 
study, showing that females pair-matched for age to males 
had less severe fibrosis in the reproductive/premenopausal/
early menopause stage, but a similar rate of fibrosis in late 
menopause compared to men [23].
It is commonly accepted that the prevalence of subjects 
with chronic alcohol abuse is almost double in males than 
in females. Chronic alcohol abuse in women is responsible 
for a more rapid transition to the more severe forms of liver 
injury because of a lower production of gastric alcohol dehy-
drogenase and of a smaller volume for alcohol distribution.
To obtain further information on gender differences in 
CLD we examined the pooled data of two Italian multicenter 
studies on the epidemiology and clinical presentation of 
CLD performed in 2001 on 9997 patients and in 2014 on 
2755 patients [16, 24–26]. Changes occurring over time in 
inter- and intra-gender differences were also evaluated.
Materials and methods
Patient enrolment
The first study was performed in 2001 (Glaxo study) and was 
made up of 9997 patients with CLD consecutively observed 
at one of 79 Italian liver units for altered hepatic biochem-
istry or positivity of hepatitis virus markers. The second 
study (Epacron study) was performed in 2014 and recruited 
2557 consecutive CLD patients in 16 Italian liver units. 
The pooled data of these 12,254 patients were analyzed to 
improve the knowledge on the epidemiological and clinical 
gender differences in CLD.
In both studies, all patients aged 18 years or more were 
enrolled as inpatients or outpatients. The participating units 
were district general or university hospitals located all over 
the country; several of them participated in both surveys 
and have cooperated for nearly 15 years in several clinical 
investigations using a similar clinical approach and analyti-
cal methods [24–28]. The staff of the liver units participat-
ing in the two surveys collected the data prospectively, had 
comparable access procedures and used a similar clinical 
approach and similar analytical methods.
Personal data were collected in full compliance with the 
Italian law on personal data protection, and each patient 
gave his/her informed consent to participate. All procedures 
applied in the two studies were in accordance with the inter-
national guidelines, with the standards of human experimen-
tation of the local Ethics Committees and with the Helsinki 
Declaration of 1975, revised in 1983. At the time of the 
first observation, each patient signed an informed consent 
for the collection of personal data. Patients who agreed to 
undergo liver biopsy signed an appropriate informed consent 
before biopsy was performed. Patients were enrolled only 
once at their first observation. For each patient, a pre-coded 
questionnaire containing demographic, epidemiological and 
clinical data was compiled. No patient refused to participate 
in the studies.
Diagnostic criteria
In both surveys, the presence of HBsAg in serum identi-
fied an HBV etiology and that of anti-HCV/HCV RNA (as 
detected by polymerase chain reaction) identified an HCV 
etiology. Autoimmune chronic hepatitis, primary biliary 
cholangitis, hereditary hemochromatosis and Wilson’s dis-
ease were diagnosed according to standardized international 
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criteria [29–33]. An alcohol intake > 40 g/day for males 
(≥ 3 drinks a day) and > 30 g/day (≥ 2 drinks a day) for 
females for at least 5 years was considered an etiological 
factor for alcohol-related liver disease.
Non-alcoholic fatty liver disease was diagnosed based on 
abnormal serum values of alanine aminotransferase (ALT) 
associated with hepatic steatosis, identified by liver histol-
ogy and/or ultrasound (US) in the absence of other known 
causes of chronic liver disease [34]. Chronic liver disease 
was considered cryptogenic in the absence of any viral, auto-
immune or metabolic etiology.
The diagnosis of chronic hepatitis was based on liver his-
tology, when available or on the persistence (> 6 months) of 
abnormal ALT in the absence of clinical, biochemical and 
US evidence of liver cirrhosis [30, 35]. The diagnosis of 
liver cirrhosis was based on liver histology or on the char-
acteristic clinical, biochemical, and US signs [29, 36]. The 
diagnosis of hepatocellular carcinoma (HCC) was based on 
histological and/or imaging findings and alfa-1-fetoprotein 
serum levels [29, 36].
Percutaneous liver biopsy (LB) was performed, if 
requested by the physician in care for diagnostic purposes, 
under US guidance using a disposable modified Menghini 
needle. At each liver unit, a skilled pathologist unaware of 
the clinical and laboratory data evaluated the liver histol-
ogy. Liver necroinflammation and fibrosis were assessed 
by the Ishak or Metavir scoring system, and standardized 
criteria were used to convert the Ishak scores to the Meta-
vir scores [37–39].
Serologic assays
Serum HBsAg and antibody to HCV were sought using 
commercial immunoenzymatic assays. HCV RNA was 
detected and quantified by a real-time PCR in a Light 
cycler 1.5 with a detection limit around 40 IU/mL (Roche 
Diagnostics, Rotkreuz, Switzerland). Routine tests were 
applied to seek the etiologic markers of autoimmune hepa-
titis, PBC, iron and copper overload and to assess liver 
functions.
Statistical analysis
The data were collected in a pre-established electronic 
CRF database (web-based data collection, e-CRF provided 
by Air-Tel®, Airon Telematica, Milan, Italy). Differences 
in the means and proportions were evaluated by Student’s 
t test and the Chi-squared test, respectively. A p value less 
than 0.05 was considered to be statistically significant. All 
p values were two-tailed.
Table 1  Comparison of the 
demographic and clinical 
features of patients by gender 
(all patients)
Some data are missing
SD standard deviation; IQR interquartile range; ns not significant to statistical analysis
Variables All patients n = 12,262 Male n = 7138 Female n = 5124 p value
Age (years) (mean ± SD) 55.3 ± 14.9 52.9 ± 15.1 58.7 ± 13.7 < 0.01
BMI (kg/m2) (mean ± SD) 25.4 ± 3.8 25.36 ± 3.5 25.1 ± 4.2 < 0.01
ALT (UI/l) (median, IQR) 53, 30–91 56, 3–97 49, 28–83.25 < 0.01
Diagnosis, N (%)
 Inactive carriers 283 (2.3) 1,77 (2.5) 106 (2.1) ns
 Chronic hepatitis 8827 (72.0) 5125 (71.8) 3702 (72.2) ns
 Liver cirrhosis 2667 (21.7) 1528 (21.4) 1139 (22.2) ns
 HCC 485 (4.0) 308 (4.3) 177 (3.5) ns
Country of origin, N (%)
 Italy 11,822 (96.4) 6892 (96.6) 4930 (96.3) ns
 Rest of the world 437 (3.6) 245 (3.4) 192 (3.7) ns
Education, N (%)
 Primary + secondary school 8675 (74.7) 4892 (72.1) 3783 (78.2) < 0.01
 High school/University 2948 (25.3) 1897 (27.9) 1051 (21.7) < 0.01
Mode of hospital admission, N (%)
 Outpatients 9250 (78.6) 5363 (78.5) 3887 (78.9) ns
 Inpatients 2511 (21.4) 1472 (21.5) 1039 (21.1) ns
Alcohol intake, N (%)
 Abstainer 6326 (53.4) 2886 (41.7) 3440 (69.6) < 0.01
 Current/past 1–2 units/day 2994 (25.2) 1878 (27.2) 1116 (22.6) < 0.01
 Current/past > 2 units/day 2538 (21.4) 2150 (31.1) 388 (7.8) < 0.01
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Results
The demographic and clinical features of the 12,263 
patients by gender are shown in Table 1. The overall male 
to female (M/F) ratio was 1.4 (7138/5124). Males were 
significantly more likely to be younger (52.9 mean age vs. 
58.7 mean age) and with more years of schooling, but less 
likely to be abstainers (41.7% vs. 69.6%; p < 0.01) com-
pared to women. No significant difference was observed 
by country of origin and mode of hospital admission. The 
stage of liver disease was similar, with a slight prepon-
derance of HCC in males. Table 2 shows the etiological 
factors of liver disease. HBV etiology and alcohol-related 
etiology (alone or associated with HBV and/or HCV) 
were more frequently detected in males, whereas females 
showed a higher proportion of HCV-related cases. NALFD 
was diagnosed with a similar frequency in both sexes. 
Other etiologies were rare.
Table 3 shows the gender differences in the three main 
etiologic groups: i.e. HBV alone, HCV alone and alcohol-
related alone. The sex ratio (M/F) was 1.99 (939/471) in the 
HBV group, 0.98 (3426/3478) in the HCV group, and 2.3 
(811/352) in the alcohol-related group.
In all three groups men were significantly more likely to 
be younger than women. Of note, the prevalence of cases 
Table 2  Etiology of liver 
disease by gender (all patients)
Some data are missing
PBC primary biliary cholangitis; NALFD non-alcoholic fatty liver disease; ns not significant to statistical 
analysis
Variables All patients 
(n = 12,262)
Male (n = 7138) Female (n = 5124) p value
HBV alone, N (%) 1410 (11.5) 939 (13.2) 471 (9.2) < 0.05
HBV plus alcohol, N (%) 172 (1.4) 147 (2.1) 25 (0.5) < 0.01
HBV plus HCV, N (%) 170 (1.4) 117 (1.6) 53 (1.0) < 0.05
HBV plus alcohol plus HCV, N (%) 72 (0.6) 62 (0.9) 10 (0.2) < 0.05
HCV alone, N (%) 6904 (56.3) 3426 (48.0) 3478 (67.9) < 0.01
HCV plus alcohol, N (%) 1313 (10.7) 1042 (14.6) 271 (5.3) < 0.01
Autoimmune hepatitis/PBC, N (%) 151 (1.25) 30 (0.4) 121 (2.4) < 0.01
Alcohol-related liver disease, N (%) 1163 (9.5) 811 (11.4) 352 (6.9) < 0.01
NAFLD, N (%) 561 (4.6) 354 (5.0) 207 (4.0) n.s
Wilson’s disease, N (%) 7 (0.1) 6 (0.1) 1 (0.02) < 0.05
Hereditary hemochromatosis, N (%) 48 (0.4) 45 (0.6) 3 (0.1) < 0.01
Cryptogenic etiology, N (%) 291 (2.4) 159 (2.2) 132 (2.6) n.s
Table 3  The demographic and clinical characteristics of the three main groups with a single etiologic factor, by gender
Some data are missing
ns not significant to statistical analysis















50.6 ± 14.1 52.8 ± 15.4 0.01 54.0 ± 15.4 59.8 ± 13.1 < 0.01 54.7 ± 13.8 57.5 ± 14.6 < 0.01
BMI, kg/m2 
M ± SD




45 (4.8%) 20 (4.2) ns
 Chronic hepa-
titis
686 (73.1%) 367 (77.9) < 0.01 2655 (77.5) 2622 (75.4) ns 487 (60.1) 217 (61.6) < 0.05
 Liver cirrhosis 169 (18.0%) 70 (14.9) < 0.05 624 (18.2) 738 (21.2) ns 126 (35.8) ns
 HCC 39 (4.2%) 14 (3.0) < 0.05 147 (4.3) 118 (3.4) ns 288 (35.5)
36 (4.4)
9 (2.6) < 0.05
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with cirrhosis in the alcohol-related group was for both gen-
ders close to 36%, a rate much higher than the corresponding 
figures observed in the HBV and HCV groups (Table 3).
To evaluate inter- and intra-gender differences over time, 
a comparison of the two studies by sex is shown in Tables 4 
and 5.
The overall sex ratio was 1.4 (5649/4103) in 2001 and 
1.5 (1489/1021) in 2014. A much higher proportion of 
women were abstainers in 2001 (70.9% vs. 36.7%), a dif-
ference no longer observed in 2014 (63.1% vs. 64.1%) due 
to the increased proportion of male abstainers; other inter-
gender differences over time are negligible. (Table 4). In 
both surveys a male preponderance was observed in HBV 
etiology (sex ratio 2.0 in 2001 and 1.9 in 2014), while in 
HCV etiology females predominated in 2001 (M/F ratio 
0.9) and males in 2014 (sex ratio 1.5) (Table 5). The M/F 
ratio both in alcohol-related liver disease and NAFLD cases 
showed a marked downtrend over time from 2.6 (710/273) 
to 1.3 (101/79), and from 1.96 (289/147) to 1.08 (65/60), 
respectively (Table 5).
The intra-gender differences over time in the two stud-
ies shows for both sexes increasing aging and an increasing 
proportion of subjects with a more severe chronic liver dis-
ease (i.e., liver cirrhosis and/or HCC). A marked increase 
in the proportion of abstainers was observed in men from 
36.7% in 2001 to 64.3% in 2014 (Table 4). In both sexes the 
proportion of HBV-related cases increased over time, while 
that of HCV-related cases increased in men (from 46.7 to 
Table 4  Comparison of the demographic and clinical features of patients in the two studies by gender
Some data are missing
ns no significant to statistical analysis
Variables 2001 Glaxo Study (n = 9752) p value 2014 Epacron Study (n = 2510) p value p value p value
Male (n = 5649) Female 
(n = 4103)
M vs. F Male (n = 1489) Female 
(n = 1021)
M vs. F M 2001 
vs. M 
2014
F 2001 vs. F 2014
Age (years) 
(mean ± SD)
51.7 ± 15.2 58.1 ± 13.8 < 0.01 57.3 ± 14.1 61.3 ± 13.1 < 0.01 < 0.01 < 0.01
BMI (kg/m2) 
(mean ± SD)
25.5 ± 3.4 25.0 ± 4.1 < 0.01 26.3 ± 3.9 25.7 ± 4.6 0.01 < 0.01 < 0.01
ALT (UI/l) 
(median, IQR)
62 (36–104) 53 (31–88) < 0.01 34 (22–58) 35 (21–63) ns < 0.01 < 0.01
Diagnosis, N (%):
 Inactive carriers 137 (2.4) 86 (2.1) ns 40 (2.7) 20 (2.0) ns ns ns
 Chronic hepa-
titis
4190 (74.2) 3052 (74.4) ns 935 (62.8) 650 (63.7) ns < 0.01 < 0.01
 Liver cirrhosis 1102 (19.5) 849 (20.7) ns 426 (28.6) 290 (28.4) ns < 0.01 < 0.05
 HCC 220 (3.9) 116 (2.8) ns 88 (5.9) 61 (6.0) ns < 0.01 < 0.01
Country of ori-
gin, N (%):
 Italy 5478 (97.0) 3969 (96.7) ns 1414 (95.0) 961 (94,3) ns < 0.05 < 0.01
 Rest of the 
world




3977 (71.7) 3212 (79.6) p < 0.01 915 (73.7) 571 (71.6) < 0.01 ns < 0.01
 High school/
University
1570 (28.3) 824 (20.4) p < 0.01 327 (26.3) 227 (28.4) < 0.05 ns < 0.01
Mode of hospital admission, N (%)
 Outpatients 4112 (76.6) 3010 (76.7) ns 1251 (85.3) 877 (87.6) ns < 0.01 < 0.01
 Inpatients 1257 (23.4) 915 (23.3) ns 215 (14.7) 124 (12.4) ns <  0.01 < 0.01
Alcohol intake, N (%)
 Abstainer 2072 (36.7) 2909 (70.9) < 0.01 814 (64.3) 531 (63.1) ns < 0.01 < 0.01
 Current/past 
1–2 units/day
1475 (26.1) 851 (20.7) < 0.01 403 (31.9) 265 (31.5) ns < 0.05 < 0.01
 Current/past 
> 2 units/day
2102 (37.2) 343 (8.4) <0.01 48 (3.8) 45 (5.4) ns < 0.01 < 0.05
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53.1%) and markedly decreased in women (from 71.2 to 
54.6%). Alcohol-related liver disease showed a downtrend 
from 12.6 to 6.8% in males (due to the increased proportion 
of abstainers), but a slight increase in women from 6.7 to 
7.7%. NAFLD slightly decreased in men (from 5.1 to 4.4%), 
but increased in women (from 3.6 to 5.9%). (Table 5).
Discussion
The 2001 and 2014 nationwide chronic hepatitis prevalence 
surveys analysed in the present study were structurally sim-
ilar. Both studies were cross-sectional and prospectively 
enrolled inpatients or outpatients aged 18 or more with 
chronic liver diseases of any etiology referring for altered 
hepatic biochemistry or positivity for hepatitis virus mark-
ers to one of the participating liver units located throughout 
the country. The same clinical approach, analytical methods 
and facilities to access the participating liver units operat-
ing in district general or university hospitals were applied. 
In addition, several of these liver units had cooperated for 
more than a decade in several clinical investigations and 
participated in both the 2001 and 2014 surveys [26, 28, 40, 
41]. Consequently, the pooling and comparison of data of 
the two studies can be considered without bias.
Males were significantly younger than females in the 
HBV, HCV and alcohol-related groups, suggesting earlier 
exposure in life. However, also another factor may explain 
this phenomenon: due to the cross-sectional structure of the 
two studies there is the potential for a survival bias, i.e. men 
might have died earlier of other diseases more likely than 
women. The two explanations are not mutually exclusive 
and both could have played a role.
The comparison of the 2001 and 2014 surveys suggests 
that the contribution over time of females to the burden of 
chronic liver diseases in Italy has significantly increased in 
alcohol-related CLD and in NALFD. The reduced M/F ratio 
in the alcohol-related etiology, alone or associated with HBV 
and/or HCV, may be attributable to the dramatic increase in 
the rate of male abstainers. These data are in line with the 
consistent linear reduction in alcohol abuse in the last dec-
ade in Italy in both sexes [39], possibly due to the efforts of 
the Italian Health Authorities to prevent alcohol abuse and 
to the economic crisis persisting in our country for over a 
decade and probably reducing the likelihood of purchasing 
alcoholic beverages.
Of interest is the shift over time in the M/F ratio from 
0.9 to 1.5 in HCV cases. This different gender trend may 
be partially explained by the substantial change in the 
abortive practice in the late seventies’ in Italy. Abortion 
in Italy before 1978 was illegal and at a high risk of expo-
sure to parenterally transmitted viruses, especially when 
hemorrhagic complications required the transfusion of 
blood units not tested at that time for anti-HCV [42, 43]. 
Abortion became legal in Italy in 1978 and, as performed 
free of charge in hospitals, illegal procedures became less 
Table 5  Etiology of liver disease in the 2001 and 2014 studies by gender
Some data are missing
ns no significant to statistical analysis
Variables 2001 Glaxo Study (n = 9752) 2014 Epacron Study (n = 2510) p value
Male (n = 5649) Female (n = 4103) Sex ratio Male (n = 1489) Female (n = 1021) Sex ratio M/F 2001 
vs. M/F 
2014
HBV alone, N (%) 651 (11.5) 320 (7.8) 2.0 288 (19.3) 151 (14.8) 1.9 ns
HBV plus alcoho, N (%) 129 (2.3) 11 (0.3) 11.7 19 (1.3) 14 (1.4) 1.4 < 0.01
HBV plus HCV, N (%) 98 (1.7) 40 (1.0) 2.5 19 (1.3) 13 (1.3) 1.5 ns
HBV plus alcohol plus HCV, 
N (%)
56 (1.0) 6 (0.1) 9.3 6 (0.4) 4 (0.4) 1.5 0.01
HCV alone, N (%) 2636 (46.7) 2921 (71.2) 0.9 790 (53.1) 557 (54.6) 1.5 < 0.01
HCV plus alcohol, N (%) 957 (16.9) 200 (4.9) 4.8 85 (5.7) 71 (7.0) 1.2 < 0.01
Autoimmune hepatitis/PBC, 
N (%)
10 (0.2) 111 (2.7) 0.1 20 (1.3) 10 (1.0) 2.0 < 0.01
Alcohol-related liver disease, 
N (%)
710 (12.6) 273 (6.7) 2.6 101 (6.8) 79 (7.7) 1.3 < 0.01
NAFLD, N (%) 289 (5.1) 147 (3.6) 2.0 65 (4.4) 60 (5.9) 1.1 < 0.01
Wilson’s Disease, N (%) 6 (0.1) 1 (0) 6.0 – – – –
Hereditary hemochromatosis, 
N (%)
45 (0.8) 3 (0.1) 15.0 – – – –
Cryptogenic etiology, N (%) 62 (1.1) 70 (1.7) 0.9 97 (61.0) 62 (6.1) 1.6 < 0.05
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frequent. The illegal practice before 1978 mostly con-
cerned women who at the time ranged in age from 18 to 
45 years. This cohort of women were 41–68 years old in 
the 2001 survey and 54–81 years old in the 2014 survey, 
when, being older, they might have had a greater likeli-
hood to have developed liver cirrhosis or HCC.
The finding that females in the HCV- and alcohol-
related groups were significantly older and with a more 
likely presence of liver cirrhosis than those in the HBV 
group (35.8 and 21.2%, respectively, versus 14.9%) might 
also reflect a biphasic course in disease progression in 
women [17] due to changes in the reproductive status 
[12, 23]. (Table 3) In fact, the increase in liver fibrosis in 
females was reported to be more rapid in late menopause 
than in the reproductive/premenopausal/early menopausal 
status [23]. In the present study, females in late meno-
pause and with more severe fibrosis were more likely to 
be included in the HCV- and alcohol-related groups than 
in the HBV group (Table 3).
NAFLD is an emerging cause of chronic liver disease in 
industrialized countries, and, consequently, of metabolic dis-
orders, due to the steady increase in the number of subjects 
with a sedentary lifestyle. In line with this tendency, the pre-
sent study shows an increasing proportion of patients with 
NAFLD from 2001 to 2014. However, it is likely that the 
prevalence of this etiology is largely underestimated in this 
and other studies because NALFD is frequently asympto-
matic and most patients seek medical care only when symp-
toms emerge. This hypothesis is supported by the data of a 
study on the general population of a small town in southern 
Italy showing NAFLD as a putative cause of 24% of cases 
with altered liver biochemistry [44]. The reduction observed 
in the M/F ratio of NAFLD cases may reflect changes over 
time in lifestyle.
Finally, the significantly older age and the higher propor-
tion of cirrhosis and HCC cases both in males and females 
in the 2014 study reflects pattern of changes over time in 
both genders.
In conclusion, this study highlights several inter- and 
intra-gender differences in the characteristics and etiologi-
cal factors of subjects with chronic liver diseases in Italy.
The presence of a potential referral biases affecting the 
figures observed should be considered: increasing atten-
tion over time to NAFLD, the availability after 2001 of 
new antiviral drugs against HBV that might have increased 
referral of HBsAg-positive patients to the prescribing liver 
units, and the tendency of patients with alcohol abuse to 
seek medical care only once symptoms of decompensation 
have started. These factors might have potentially affected 
the true prevalences and characteristics of CLD influencing 
the intra-gender disparity observed, but not the inter-gender 
differences, as both sexes have been exposed to the same 
possible selective factors.
The availability of effective drugs to counteract HBV 
infection (entecavir, tenofovir) and HCV infection DAA 
(direct acting antivirals), the great effectiveness of HBV 
universal vaccination and recent acquisitions of antiandro-
genic and estrogen/estradiol capacity to delay the develop-
ment of cirrhosis offers new perspectives in the study of 
CLDs. Published data indicate that hormone replacement 
therapy in post-menopausal or ovariectomized women 
slows the progression of fibrosis, suggesting that estra-
diol may play an anti-fibrotic or antiviral action [45–47], 
but further studies are needed to better define the nature 
and the extent of this action. The availability of effective 
nucleotide/nucleoside analogues to suppress HBV repli-
cation and the effective universal vaccination campaign 
against hepatitis B, at present covering all Italian subjects 
aged 0–35, have reduced and will increasingly reduce the 
importance of HBV infection in Italy. This infection, how-
ever, remains a heavy burden for the national healthcare 
system of Italy, where the huge flow of migrants arriving 
from countries with moderate or high HBV endemicity 
poses major screening and vaccination problems. Finally, 
representing the end-stage Italian observational findings 
of HCV related CLD, the data of the present study may be 
used as a reference to evaluate the effectiveness of DAA 
therapy in Italy.
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